Canaccord Genuity Reiterates a 'Buy' on Insulet Corporation (PODD); Solid Q1; Gen2 Pod Still Awaiting FDA Clearance

May 10, 2012 10:42 AM EDT
Get Alerts PODD Hot Sheet
Price: $148.16 +0.88%

Rating Summary:
    22 Buy, 17 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Insulet Corporation (NASDAQ: PODD) price target of $27.00.

Analyst, William J. Plovanic, said, "We reiterate our rating on Insulet after a solid financial performance in Q1/12. However, we note the delay in FDA clearance for the next generation OmniPod, the Eros, will likely overshadow financial results. We note that we are modeling for the Gen2 Pod to gain FDA clearance in late 2012, and therefore do not have an acceleration in growth or improvement in margins baked into our 2012 projections."

For an analyst ratings summary and ratings history on Insulet Corporation click here. For more ratings news on Insulet Corporation click here.

Shares of Insulet Corporation closed at $17.31 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View

Related Entities

Earnings